Shares of ViroPharma (VPHM) sink 18.4% premarket after rivals Watson Pharmaceuticals and Akorn...
Shares of ViroPharma (VPHM) sink 18.4% premarket after rivals Watson Pharmaceuticals and Akorn (AKRX) both launch generic versions of Vancocin. The company says that it intends to file a complaint seeking an injunction to set aside the FDA approvals on the drugs and restore its exclusivity.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Investor's Business Daily (Feb 12, 2015)
at Investor's Business Daily (Jan 26, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at Benzinga.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs